Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NeuroSense Therapeutics Ltd. Developing combination therapies for neurodegenerative diseases, with a focus on ALS.	United States of America	NRSN
NewAmsterdam Pharma Co N.V. Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.	United States of America	NAMS
Newbury Pharmaceuticals AB Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.	Sweden	NEWBRY
New Nordic Healthbrands AB Develops and markets herbal supplements & beauty products for natural wellness consumers globally.	Sweden	NNH
Newron Pharmaceuticals S.p.A. Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.	Italy	NWRN
NEXGEL, INC. Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.	United States of America	NXGL
NextCell Pharma AB Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.	Sweden	NXTCL
NextCure, Inc. Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.	United States of America	NXTC
NGeneBio Co., Ltd. Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.	South Korea	354200
NIBEC CO., LTD. Biotech CDMO creating regenerative products with peptide and biomaterial technologies.	South Korea	138610